PD-L1 Dysregulation in COVID-19 Patients
The COVID-19 pandemic has reached direct and indirect medical and social consequences with a subset of patients who rapidly worsen and die from severe-critical manifestations. As a result, there is still an urgent need to identify prognostic biomarkers and effective therapeutic approaches. Severe-cr...
Main Authors: | , , , , , , , , , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2021-06-01
|
Series: | Frontiers in Immunology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2021.695242/full |
id |
doaj-76352fb4b43048be81e497882e05dd08 |
---|---|
record_format |
Article |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Francesco Sabbatino Francesco Sabbatino Valeria Conti Valeria Conti Gianluigi Franci Gianluigi Franci Carmine Sellitto Carmine Sellitto Valentina Manzo Valentina Manzo Pasquale Pagliano Pasquale Pagliano Emanuela De Bellis Emanuela De Bellis Alfonso Masullo Francesco Antonio Salzano Francesco Antonio Salzano Alessandro Caputo Alessandro Caputo Ilaria Peluso Pio Zeppa Pio Zeppa Giosuè Scognamiglio Giuseppe Greco Carla Zannella Michele Ciccarelli Michele Ciccarelli Claudia Cicala Carmine Vecchione Carmine Vecchione Amelia Filippelli Amelia Filippelli Stefano Pepe Stefano Pepe |
spellingShingle |
Francesco Sabbatino Francesco Sabbatino Valeria Conti Valeria Conti Gianluigi Franci Gianluigi Franci Carmine Sellitto Carmine Sellitto Valentina Manzo Valentina Manzo Pasquale Pagliano Pasquale Pagliano Emanuela De Bellis Emanuela De Bellis Alfonso Masullo Francesco Antonio Salzano Francesco Antonio Salzano Alessandro Caputo Alessandro Caputo Ilaria Peluso Pio Zeppa Pio Zeppa Giosuè Scognamiglio Giuseppe Greco Carla Zannella Michele Ciccarelli Michele Ciccarelli Claudia Cicala Carmine Vecchione Carmine Vecchione Amelia Filippelli Amelia Filippelli Stefano Pepe Stefano Pepe PD-L1 Dysregulation in COVID-19 Patients Frontiers in Immunology SARS-CoV-2 PD-L1 immune checkpoint molecules innate immune response adaptive immune response COVID-19 |
author_facet |
Francesco Sabbatino Francesco Sabbatino Valeria Conti Valeria Conti Gianluigi Franci Gianluigi Franci Carmine Sellitto Carmine Sellitto Valentina Manzo Valentina Manzo Pasquale Pagliano Pasquale Pagliano Emanuela De Bellis Emanuela De Bellis Alfonso Masullo Francesco Antonio Salzano Francesco Antonio Salzano Alessandro Caputo Alessandro Caputo Ilaria Peluso Pio Zeppa Pio Zeppa Giosuè Scognamiglio Giuseppe Greco Carla Zannella Michele Ciccarelli Michele Ciccarelli Claudia Cicala Carmine Vecchione Carmine Vecchione Amelia Filippelli Amelia Filippelli Stefano Pepe Stefano Pepe |
author_sort |
Francesco Sabbatino |
title |
PD-L1 Dysregulation in COVID-19 Patients |
title_short |
PD-L1 Dysregulation in COVID-19 Patients |
title_full |
PD-L1 Dysregulation in COVID-19 Patients |
title_fullStr |
PD-L1 Dysregulation in COVID-19 Patients |
title_full_unstemmed |
PD-L1 Dysregulation in COVID-19 Patients |
title_sort |
pd-l1 dysregulation in covid-19 patients |
publisher |
Frontiers Media S.A. |
series |
Frontiers in Immunology |
issn |
1664-3224 |
publishDate |
2021-06-01 |
description |
The COVID-19 pandemic has reached direct and indirect medical and social consequences with a subset of patients who rapidly worsen and die from severe-critical manifestations. As a result, there is still an urgent need to identify prognostic biomarkers and effective therapeutic approaches. Severe-critical manifestations of COVID-19 are caused by a dysregulated immune response. Immune checkpoint molecules such as Programmed death-1 (PD-1) and its ligand programmed death-ligand 1 (PD-L1) play an important role in regulating the host immune response and several lines of evidence underly the role of PD-1 modulation in COVID-19. Here, by analyzing blood sample collection from both hospitalized COVID-19 patients and healthy donors, as well as levels of PD-L1 RNA expression in a variety of model systems of SARS-CoV-2, including in vitro tissue cultures, ex-vivo infections of primary epithelial cells and biological samples obtained from tissue biopsies and blood sample collection of COVID-19 and healthy individuals, we demonstrate that serum levels of PD-L1 have a prognostic role in COVID-19 patients and that PD-L1 dysregulation is associated to COVID-19 pathogenesis. Specifically, PD-L1 upregulation is induced by SARS-CoV-2 in infected epithelial cells and is dysregulated in several types of immune cells of COVID-19 patients including monocytes, neutrophils, gamma delta T cells and CD4+ T cells. These results have clinical significance since highlighted the potential role of PD-1/PD-L1 axis in COVID-19, suggest a prognostic role of PD-L1 and provide a further rationale to implement novel clinical studies in COVID-19 patients with PD-1/PD-L1 inhibitors. |
topic |
SARS-CoV-2 PD-L1 immune checkpoint molecules innate immune response adaptive immune response COVID-19 |
url |
https://www.frontiersin.org/articles/10.3389/fimmu.2021.695242/full |
work_keys_str_mv |
AT francescosabbatino pdl1dysregulationincovid19patients AT francescosabbatino pdl1dysregulationincovid19patients AT valeriaconti pdl1dysregulationincovid19patients AT valeriaconti pdl1dysregulationincovid19patients AT gianluigifranci pdl1dysregulationincovid19patients AT gianluigifranci pdl1dysregulationincovid19patients AT carminesellitto pdl1dysregulationincovid19patients AT carminesellitto pdl1dysregulationincovid19patients AT valentinamanzo pdl1dysregulationincovid19patients AT valentinamanzo pdl1dysregulationincovid19patients AT pasqualepagliano pdl1dysregulationincovid19patients AT pasqualepagliano pdl1dysregulationincovid19patients AT emanueladebellis pdl1dysregulationincovid19patients AT emanueladebellis pdl1dysregulationincovid19patients AT alfonsomasullo pdl1dysregulationincovid19patients AT francescoantoniosalzano pdl1dysregulationincovid19patients AT francescoantoniosalzano pdl1dysregulationincovid19patients AT alessandrocaputo pdl1dysregulationincovid19patients AT alessandrocaputo pdl1dysregulationincovid19patients AT ilariapeluso pdl1dysregulationincovid19patients AT piozeppa pdl1dysregulationincovid19patients AT piozeppa pdl1dysregulationincovid19patients AT giosuescognamiglio pdl1dysregulationincovid19patients AT giuseppegreco pdl1dysregulationincovid19patients AT carlazannella pdl1dysregulationincovid19patients AT micheleciccarelli pdl1dysregulationincovid19patients AT micheleciccarelli pdl1dysregulationincovid19patients AT claudiacicala pdl1dysregulationincovid19patients AT carminevecchione pdl1dysregulationincovid19patients AT carminevecchione pdl1dysregulationincovid19patients AT ameliafilippelli pdl1dysregulationincovid19patients AT ameliafilippelli pdl1dysregulationincovid19patients AT stefanopepe pdl1dysregulationincovid19patients AT stefanopepe pdl1dysregulationincovid19patients |
_version_ |
1721392871335002112 |
spelling |
doaj-76352fb4b43048be81e497882e05dd082021-06-07T05:55:02ZengFrontiers Media S.A.Frontiers in Immunology1664-32242021-06-011210.3389/fimmu.2021.695242695242PD-L1 Dysregulation in COVID-19 PatientsFrancesco Sabbatino0Francesco Sabbatino1Valeria Conti2Valeria Conti3Gianluigi Franci4Gianluigi Franci5Carmine Sellitto6Carmine Sellitto7Valentina Manzo8Valentina Manzo9Pasquale Pagliano10Pasquale Pagliano11Emanuela De Bellis12Emanuela De Bellis13Alfonso Masullo14Francesco Antonio Salzano15Francesco Antonio Salzano16Alessandro Caputo17Alessandro Caputo18Ilaria Peluso19Pio Zeppa20Pio Zeppa21Giosuè Scognamiglio22Giuseppe Greco23Carla Zannella24Michele Ciccarelli25Michele Ciccarelli26Claudia Cicala27Carmine Vecchione28Carmine Vecchione29Amelia Filippelli30Amelia Filippelli31Stefano Pepe32Stefano Pepe33Department of Medicine, Surgery and Dentistry, “Scuola Medica Salernitana”, University of Salerno, Baronissi (SA), ItalyOncology Unit, San Giovanni di Dio e Ruggi D’Aragona University Hospital, Salerno, ItalyDepartment of Medicine, Surgery and Dentistry, “Scuola Medica Salernitana”, University of Salerno, Baronissi (SA), ItalyPharmacology Unit, San Giovanni di Dio e Ruggi D’Aragona University Hospital, Salerno, ItalyDepartment of Medicine, Surgery and Dentistry, “Scuola Medica Salernitana”, University of Salerno, Baronissi (SA), ItalyClinical Pathology and Microbiology Unit, San Giovanni di Dio e Ruggi D’Aragona University Hospital, Salerno, ItalyDepartment of Medicine, Surgery and Dentistry, “Scuola Medica Salernitana”, University of Salerno, Baronissi (SA), ItalyPharmacology Unit, San Giovanni di Dio e Ruggi D’Aragona University Hospital, Salerno, ItalyDepartment of Medicine, Surgery and Dentistry, “Scuola Medica Salernitana”, University of Salerno, Baronissi (SA), ItalyPharmacology Unit, San Giovanni di Dio e Ruggi D’Aragona University Hospital, Salerno, ItalyDepartment of Medicine, Surgery and Dentistry, “Scuola Medica Salernitana”, University of Salerno, Baronissi (SA), ItalyInfectious Disease Unit, San Giovanni di Dio e Ruggi D’Aragona University Hospital, Salerno, ItalyDepartment of Medicine, Surgery and Dentistry, “Scuola Medica Salernitana”, University of Salerno, Baronissi (SA), ItalyPharmacology Unit, San Giovanni di Dio e Ruggi D’Aragona University Hospital, Salerno, ItalyInfectious Disease Unit, San Giovanni di Dio e Ruggi D’Aragona University Hospital, Salerno, ItalyDepartment of Medicine, Surgery and Dentistry, “Scuola Medica Salernitana”, University of Salerno, Baronissi (SA), ItalyOtolaryngology Unit, San Giovanni di Dio e Ruggi D’Aragona University Hospital, Salerno, ItalyDepartment of Medicine, Surgery and Dentistry, “Scuola Medica Salernitana”, University of Salerno, Baronissi (SA), ItalyPathology Unit, San Giovanni di Dio e Ruggi D’Aragona University Hospital, Salerno, ItalyHematology Unit, AORN Cardarelli Hospital, Naples, ItalyDepartment of Medicine, Surgery and Dentistry, “Scuola Medica Salernitana”, University of Salerno, Baronissi (SA), ItalyPathology Unit, San Giovanni di Dio e Ruggi D’Aragona University Hospital, Salerno, ItalyPathology Unit, Istituto Nazionale Tumori, IRCSS, “Fondazione G Pascale”, Naples, Italy0Section of Microbiology and Virology, University Hospital “Luigi Vanvitelli”, Naples, Italy1Department of Experimental Medicine, University of Campania “Luigi Vanvitelli”, Naples, ItalyDepartment of Medicine, Surgery and Dentistry, “Scuola Medica Salernitana”, University of Salerno, Baronissi (SA), Italy2Cardiology Unit, San Giovanni di Dio e Ruggi D’Aragona University Hospital, Salerno, Italy3Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, Bethesda, MD, United StatesDepartment of Medicine, Surgery and Dentistry, “Scuola Medica Salernitana”, University of Salerno, Baronissi (SA), Italy4Vascular Pathophysiology Unit, IRCCS Neuromed, Pozzilli, ItalyDepartment of Medicine, Surgery and Dentistry, “Scuola Medica Salernitana”, University of Salerno, Baronissi (SA), ItalyPharmacology Unit, San Giovanni di Dio e Ruggi D’Aragona University Hospital, Salerno, ItalyDepartment of Medicine, Surgery and Dentistry, “Scuola Medica Salernitana”, University of Salerno, Baronissi (SA), ItalyOncology Unit, San Giovanni di Dio e Ruggi D’Aragona University Hospital, Salerno, ItalyThe COVID-19 pandemic has reached direct and indirect medical and social consequences with a subset of patients who rapidly worsen and die from severe-critical manifestations. As a result, there is still an urgent need to identify prognostic biomarkers and effective therapeutic approaches. Severe-critical manifestations of COVID-19 are caused by a dysregulated immune response. Immune checkpoint molecules such as Programmed death-1 (PD-1) and its ligand programmed death-ligand 1 (PD-L1) play an important role in regulating the host immune response and several lines of evidence underly the role of PD-1 modulation in COVID-19. Here, by analyzing blood sample collection from both hospitalized COVID-19 patients and healthy donors, as well as levels of PD-L1 RNA expression in a variety of model systems of SARS-CoV-2, including in vitro tissue cultures, ex-vivo infections of primary epithelial cells and biological samples obtained from tissue biopsies and blood sample collection of COVID-19 and healthy individuals, we demonstrate that serum levels of PD-L1 have a prognostic role in COVID-19 patients and that PD-L1 dysregulation is associated to COVID-19 pathogenesis. Specifically, PD-L1 upregulation is induced by SARS-CoV-2 in infected epithelial cells and is dysregulated in several types of immune cells of COVID-19 patients including monocytes, neutrophils, gamma delta T cells and CD4+ T cells. These results have clinical significance since highlighted the potential role of PD-1/PD-L1 axis in COVID-19, suggest a prognostic role of PD-L1 and provide a further rationale to implement novel clinical studies in COVID-19 patients with PD-1/PD-L1 inhibitors.https://www.frontiersin.org/articles/10.3389/fimmu.2021.695242/fullSARS-CoV-2PD-L1immune checkpoint moleculesinnate immune responseadaptive immune responseCOVID-19 |